ECSP12011837A - Derivados de pirazol que modulan la estearoil-coa-desaturasa - Google Patents

Derivados de pirazol que modulan la estearoil-coa-desaturasa

Info

Publication number
ECSP12011837A
ECSP12011837A ECSP12011837A ECSP12011837A EC SP12011837 A ECSP12011837 A EC SP12011837A EC SP12011837 A ECSP12011837 A EC SP12011837A EC SP12011837 A ECSP12011837 A EC SP12011837A
Authority
EC
Ecuador
Prior art keywords
modulate
coa
desaturasa
estearoil
derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Jianmin Fu
Natalie Dales
Natalia Pokrovskaia
Qi Jia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011837(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of ECSP12011837A publication Critical patent/ECSP12011837A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona derivados heterocíclicos que modulan la actividad de la estearoil-CoA-desaturasa. También se abarcan los métodos para utilizar estos derivados con el fin de modular la actividad de la estearoil-CoA-desaturasa, y las composiciones farmacéuticas que comprenden estos derivados.
ECSP12011837 2009-10-01 2012-04-27 Derivados de pirazol que modulan la estearoil-coa-desaturasa ECSP12011837A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24763409P 2009-10-01 2009-10-01

Publications (1)

Publication Number Publication Date
ECSP12011837A true ECSP12011837A (es) 2012-06-29

Family

ID=43066810

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011837 ECSP12011837A (es) 2009-10-01 2012-04-27 Derivados de pirazol que modulan la estearoil-coa-desaturasa

Country Status (23)

Country Link
US (1) US20130011361A1 (es)
EP (1) EP2483264A1 (es)
JP (1) JP2013506638A (es)
KR (1) KR20120080226A (es)
CN (1) CN102574841A (es)
AU (1) AU2010302577A1 (es)
BR (1) BR112012007509A2 (es)
CA (1) CA2776294A1 (es)
CL (1) CL2012000797A1 (es)
CO (1) CO6761294A2 (es)
CR (1) CR20120134A (es)
EA (1) EA201200545A1 (es)
EC (1) ECSP12011837A (es)
IL (1) IL218294A0 (es)
IN (1) IN2012DN01913A (es)
MA (1) MA33693B1 (es)
MX (1) MX2012003938A (es)
PE (1) PE20121439A1 (es)
PH (1) PH12012500648A1 (es)
SG (1) SG178869A1 (es)
TN (1) TN2012000085A1 (es)
WO (1) WO2011039358A1 (es)
ZA (1) ZA201201390B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
RU2269354C2 (ru) 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
PT1315831E (pt) 2000-02-24 2010-11-04 Xenon Pharmaceuticals Inc Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos
CA2430987A1 (en) 2000-09-26 2002-04-04 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
PE20110341A1 (es) * 2006-08-15 2011-06-21 Novartis Ag COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
AU2007288245A1 (en) * 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
JP5351025B2 (ja) * 2006-09-22 2013-11-27 ノバルティス アーゲー ヘテロ環式有機化合物
US8068738B2 (en) * 2007-02-21 2011-11-29 Tte Technology, Inc. System and method for decoding infra-red (IR) signals
PE20091473A1 (es) * 2008-02-20 2009-10-23 Novartis Ag Heterociclos como inhibidores de esteaoril-coa desaturasa

Also Published As

Publication number Publication date
KR20120080226A (ko) 2012-07-16
MX2012003938A (es) 2012-08-03
CL2012000797A1 (es) 2013-08-09
TN2012000085A1 (en) 2013-09-19
ZA201201390B (en) 2012-10-31
BR112012007509A2 (pt) 2016-11-22
IL218294A0 (en) 2012-04-30
JP2013506638A (ja) 2013-02-28
PE20121439A1 (es) 2012-11-06
PH12012500648A1 (en) 2012-11-12
MA33693B1 (fr) 2012-10-01
IN2012DN01913A (es) 2015-07-24
CO6761294A2 (es) 2013-09-30
CA2776294A1 (en) 2011-04-07
EP2483264A1 (en) 2012-08-08
AU2010302577A1 (en) 2012-03-15
CN102574841A (zh) 2012-07-11
EA201200545A1 (ru) 2012-12-28
CR20120134A (es) 2012-05-17
WO2011039358A1 (en) 2011-04-07
US20130011361A1 (en) 2013-01-10
SG178869A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CU20100262A7 (es) Compuestos orgánicos
CO6290655A2 (es) Inhibidors heterociclicos de estearoil-coa-desaturasa
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
MX2019010602A (es) Inhibidores de cdk.
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2011002258A1 (es) Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih.
MX2009013043A (es) Antioxidante para alimentos.
CL2012001485A1 (es) Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion.
GT201100039A (es) Agentes antifúngicos
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
ECSP10010292A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20120052A7 (es) Derivados de pirazol que modulan estearoil-coa-desaturasa
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa
TN2010000598A1 (en) Organic compounds